Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Page Path

HOME
ARTICLE CATEGORY
Review

Review

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 5658 Download: 204 Web of Science: 21 Crossref: 20

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 8858 Download: 313 Web of Science: 30 Crossref: 35

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 7914 Download: 346 Web of Science: 43 Crossref: 44

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 7298 Download: 303 Web of Science: 12 Crossref: 12

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 5995 Download: 236 Web of Science: 15 Crossref: 15

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 6485 Download: 267 Web of Science: 30 Crossref: 32

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 7039 Download: 322 Web of Science: 22 Crossref: 22

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 6869 Download: 273 Web of Science: 43 Crossref: 48

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 5295 Download: 127 Web of Science: 4 Crossref: 4

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 20920 Download: 688 Web of Science: 300 Crossref: 338

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 8974 Download: 368 Web of Science: 23 Crossref: 26

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 4893 Download: 227 Web of Science: 19 Crossref: 21

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 5397 Download: 160 Web of Science: 13 Crossref: 14

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 4786 Download: 133 Web of Science: 12 Crossref: 12

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 12520 Download: 614 Web of Science: 113 Crossref: 114

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 8605 Download: 290 Web of Science: 26 Crossref: 32

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 7873 Download: 246 Web of Science: 19 Crossref: 19

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 6548 Download: 271 Web of Science: 15 Crossref: 18

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 16484 Download: 809 Web of Science: 104 Crossref: 110

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park, Young S. Hahn

Clin Mol Hepatol. 2023;29(1):65-76. Published online August 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0032

View: 7094 Download: 191 Web of Science: 21 Crossref: 22

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 7416 Download: 270 Web of Science: 38 Crossref: 40

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 9453 Download: 304 Web of Science: 34 Crossref: 37

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0104

View: 14239 Download: 1,057 Web of Science: 30 Crossref: 30

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 11317 Download: 203 Web of Science: 13 Crossref: 14

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 9587 Download: 538 Web of Science: 51 Crossref: 51

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 7042 Download: 266 Web of Science: 42 Crossref: 46

Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology

Sung Hak Lee, Hyun-Jong Jang

Clin Mol Hepatol. 2022;28(4):754-772. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2021.0394

View: 7361 Download: 257 Web of Science: 15 Crossref: 14

Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review

Sang Jin Kim, Jong Man Kim

Clin Mol Hepatol. 2022;28(4):739-753. Published online April 26, 2022

DOI: https://doi.org/10.3350/cmh.2022.0060

View: 6444 Download: 193 Web of Science: 22 Crossref: 22

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 6463 Download: 266 Web of Science: 15 Crossref: 18

The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology

Youngseok Lee, Jong-Hoon Kim

Clin Mol Hepatol. 2022;28(4):706-724. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0390

View: 15127 Download: 296 Web of Science: 20 Crossref: 21

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 12182	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7614	MAFLD: How is it different from NAFLD?
Viewed By 6633	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5875	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5478	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 338	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis